1. 794 Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors. (10th December 2020) Authors: Moreno, Victor; Gaudy-Marqueste, Caroline; Wermke, Martin; Italiano, Antoine; Romano, Emanuela; Marabelle, Aurelien; Connors, Emilee; Zhou, Heng; Dobrenkov, Konstantin; Chartash, Elliot; Calvo, Emiliano; Aller, Emiliano Calvo Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A474 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. (May 2020) Authors: Lala, Mallika; Li, Tommy Ruosi; de Alwis, Dinesh P.; Sinha, Vikram; Mayawala, Kapil; Yamamoto, Noboru; Siu, Lillian L.; Chartash, Elliot; Aboshady, Hesham; Jain, Lokesh Journal: European journal of cancer Issue: Volume 131(2020) Page Start: 68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Corrigendum to "A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation" [Eur J Canc 131 (2020) 68–75]. (February 2021) Authors: Lala, Mallika; Li, Tommy Ruosi; de Alwis, Dinesh P.; Sinha, Vikram; Mayawala, Kapil; Li, Mengyao; Yamamoto, Noboru; Siu, Lillian L.; Chartash, Elliot; Aboshady, Hesham; Jain, Lokesh Journal: European journal of cancer Issue: Volume 144(2021) Page Start: 400 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. Issue 22 (18th August 2020) Authors: Geva, Ravit; Voskoboynik, Mark; Dobrenkov, Konstantin; Mayawala, Kapil; Gwo, Jennifer; Wnek, Richard; Chartash, Elliot; Long, Georgina V. Journal: Cancer Issue: Volume 126:Issue 22(2020) Page Start: 4926 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. O83 Phase 1 study of an anti-CD27 agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. (15th April 2020) Authors: Shapira-Frommer, Ronnie; Dongen, Marloes GJ van; Dobrenkov, Konstantin; Chartash, Elliot; Liu, Fang; Li, Claire; Wnek, Richard; Patel, Manish Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 1 Page Start: A2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy. Issue 9 (13th September 2022) Authors: Guelen, Lars; Fischmann, Thierry O; Wong, Jerelyn; Mauze, Smita; Guadagnoli, Marco; Bąbała, Nikolina; Wagenaars, Jozef; Juan, Veronica; Rosen, David; Prosise, Winnie; Habraken, Maurice; Lodewijks, Imke; Gu, Danling; Stammen-Vogelzangs, Judith; Yu, Ying; Baker, Jeanne; Lutje Hulsik, David; Driesse... Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 9(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗